Nu-Seals Cardio (Acetylsalicylic Acid)

Acetylsalicylic Acid, the active ingredient in Nu-Seals Cardio, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as a tablet for oral use. It is employed as an antiplatelet agent to reduce the risk of cardiovascular events in adults. GNH USA supplies Nu-Seals Cardio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nu-Seals Cardio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nu‑Seals Cardio is an antiplatelet medication that acts on platelet aggregation pathways to lower thrombotic risk.

- Acute coronary syndrome: helps prevent further myocardial injury and recurrent ischemic events. - Post‑myocardial infarction: reduces the risk of subsequent heart attacks and cardiovascular death. - Stroke prevention in patients with a history of ischemic stroke or transient ischemic attack: lowers recurrence risk. - Peripheral arterial disease: diminishes the chance of limb‑related ischemic complications. - Primary prevention in high‑risk adults: modestly reduces first‑time cardiovascular events when risk outweighs bleeding concerns.

Adverse reactions to Nu‑Seals Cardio vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Minor bruising or easy bleeding from cuts. - Nausea or mild stomach upset. - Heartburn or acid reflux symptoms. - Headache.

Serious or Rare Side Effects: - Gastrointestinal ulceration or serious bleeding. - Intracranial hemorrhage. - Severe allergic reactions such as anaphylaxis. - Renal impairment or acute kidney injury. - Reye syndrome in children and adolescents. - Thrombocytopenia or other blood dyscrasias.

When prescribing Nu‑Seals Cardio, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Bleeding risk assessment: review history of ulcers, anticoagulant use, or coagulopathy. - Gastrointestinal protection: consider a proton‑pump inhibitor in patients with prior ulcer disease. - Renal function monitoring: adjust use in patients with chronic kidney disease. - Asthma caution: avoid in patients with aspirin‑exacerbated respiratory disease. - Pregnancy and lactation: use only if clearly indicated and benefits outweigh risks. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nu‑Seals Cardio can alter the safety or efficacy of several concomitant medicines. Proper review of a patient’s medication list is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Selective COX‑2 inhibitors (e.g., celecoxib): additive gastrointestinal toxicity. - Corticosteroids: heightened risk of gastrointestinal ulceration.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs (e.g., sertraline, venlafaxine): may modestly increase bleeding. - ACE inhibitors or ARBs: can affect renal perfusion when combined with NSAID effect. - Diuretics: potential for reduced renal clearance of aspirin.